This represents the first time that patient-reported outcomes have been reported in both COURAGE-like and non COURAGE-like patients exclusively receiving a DES. Although there were no differences in clinical outcomes, marked improvements in patient's health status were observed 12 months after XIENCE V. QoL significantly improved with the two groups behaving similarly over time. There were consistent improvements in QoL across all angina burden cohorts with improvements occurring early, being sustained for 1 year and most notable when angina burdens were greatest. These data extend patient's perspectives on the benefits of PCI.
Background:
The PRO Kinetic Energy is a thin strut (60 μm) cobalt chromium alloy (L605) bare metal stent, which is completely coated with a thin layer of amorphous silicon carbide PROBIO. The aim of this registry is to evaluate the clinical performance of the PRO-Kinetic Energy stent system in a large patient population in standard clinical care. Methods: Between April 09, and November 09, 2010, 1'016 subjects presenting with de-novo and re-stenotic coronary artery lesions were consecutively enrolled in this international, multicentric ENERGY Registry. Primary safety endpoint was MACE (composite of cardiac death, clinically driven TLR, myocardial infarction and acute myocardial infarction) at six-month follow-up. Additional follow-up assessments are defined in the protocol for 12 and 24 months. Quality of Life (EQ-5D) evaluation will be performed in a subgroup on all follow-up intervals. Following subgroups were prespecified: diabetes, AMI, unstable angina, small vessel (< 2.75 mm) and elderly patients (> 75 yrs). Results: Seven hundred eighty-nine men (78%) with a mean age of 66 ± 12.5, ranging from 27 -96 years, were enrolled in 48 sites in 10 countries. The majority of the subjects presented with hypertension (71%), hyperlipidemia (68%) smoker (31%), diabetes (16%). Fourteen percent of the patients experienced unstable angina. ACS due to MI was seen in 452 patients. The portion of elderly patients is represented by 19%. Type A (21%), B1 (40%), B2 (29%) and C (10%) lesions were seen in this cohort. Eighty-six percent (874/1016) follow up compliance at six-month follow-up was achieved. MACE (hierachical) occurred in 4.7% subjects between baseline and 6month follow-up including 2.5% target lesion revascularizations,2.3% stent thrombosis, 1.5% myocardial infarctions (incl. AMI) and 0.7% cardiac death. Conclusion: New generation bare metal stents (BMS) like the PRO-Kinetic Energy with very thin struts and passive coating show a very low rate of MACE compared to previous BMS. Utility of such modern BMS platforms are still very relevant in the era of DES. Background: The minimally invasive direct coronary artery bypassing (MIDCAB) has proven its superiority over bare metal stenting of proximal left anterior descending (LAD) artery in reducing the need of repeated revascularizations. Nevertheless, the long term outcome of percutaneous coronary intervention (PCI) utilizing new generation of drug eluting stenting (DES), in this lesion subset is unknown. Methods: This is a multicenter retrospective registry of 463 consecutive patients, enrolled between 2004 and 2009 with proximal, significant, type B and C LAD lesion (>70% DS) who underwent either PCI with exclusive use of DES (72% of 2nd. generation) or MIDCAB. We excluded patients with myocardial infarction (MI) on admission, concomitant lesions in the right and/or circumflex coronary arteries, previous PCI within 6 months, or previous CABG . A propensity score was utilized for patients baseline characteristics matching and results adjustment. Results: One hundred and eighty seven patients underwent PCI with DES while 276 MIDCAB. Patients in PCI group were older (63,6 ± 9,3 vs. 59,7 ± 10,2 y.o.; p<0,05), more often female (32 vs. 21%; p<0,01) had higher CCS class (2,53 ± 0,9 vs. 2 ± 0,3; p<0,01), higher Euroscore (4 vs. 2,2; p<0,01) and more often presented with peripheral artery disease (8 vs. 2%; p<0,01). At 30 day follow up there was no death in both groups. There were also no differences in the occurrence of major adverse cardiovascular and cerebral events (MACCE) defined as death, stroke, myocardial infarction or repeated revascularization between PCI and MIDCAB groups (0% vs. 0,7%;p=0,22). However there were less serious adverse events (SAE) defined as atrial fibrillation, wound infection, low output syndrome or serious bleeding in patients who underwent MIDCAB (0 vs. 5%; p<0,01). After adjustment at 5 year follow up there were no differences in survival (93,5 vs. 95,7%; p=0,56), MACCE free survival (64,9 vs. 74,4%, p=0,12) and MI -free survival (94,9 vs. 95.8%; p=0,46) between PCI and MIDCAB respectively. There was significantly higher freedom from repeated revascularization in patients who underwent MIDCAB (86,4 vs. 64,1%; p=0,01). Conclusion: Both procedures show exceptional safety, with no deaths and only minor adverse events rate at periprocedural period. At long term PCI with DES is non inferior to MIDCAB with regard to safety endpoints. The rate of repeated revascularizations remained higher in the PCI group 
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www.JACC.TCTAbstracts2011 differ between groups. In patients receiving second generation DES, more multivessel PCI were performed (p=0.01). The overall incidence of PMI was 4.75%. Between first and second generation DES, there was no significant difference in PMI (5.5% vs.4.0%; p=0.29). In a multivariate analysis, only the total number of stents implanted (p<0.001) and presentation with acute coronary syndrome (p=0.02) were independent predictors of PMI. 
Conclusion:
Using the revised ARC definition of PMI, there was no significant difference in PMI between first and second generation DES following routine clinical PCI.
TCT-202 The Difference of Predictors for Occurrence of Instent Restenosis in the underexpanded or non under-expanded post-DES implantation : An intravascular ultrasound analysis from multicenter, randomized trials
Ki-Woon Kang 1 , Byeong-Keuk Kim 1 , Young-Guk Ko 1 , Dong-Ho Shin 1 , Jung-Sun Kim 1 , Donghoon Choi 1 , Yangsoo Jang 1, 2 , Myeong-Ki Hong 1, 2 1 Severance Cardiovascular Hospital, Seoul, Republic of Korea; 2 Severance Biomedical Science Institute, Seoul, Republic of Korea Background: Stent underexpansion (SUE), defined by minimal stent CSA (MSA < 5 mm2), is the one of the most important predictor of in-stent restenosis (ISR) in the era of drug-eluting stent (DES) implantation. However, the difference of predictors for occurrence of ISR between SUE and non-SUE might not be well known. Methods: The EXCELLENT and POET were a multicenter, randomized trial comparing paclitaxel-eluting stent (PES) (n=121), sirolimus-eluting stent (SES), zotarolimus-eluting stent (ZES) and everolimus-eluting stent (EES) in patients with stable or unstable angina. Angiographically ISR at follow-up was observed in 450 lesions treated with DES implantation. A total 393 of enrolled patients who underwent post-intervention and 9-month follow-up IVUS investigation were followed clinically for 3-year period (PES n=121, SES n=161, ZES n=59, EES n=52). We classified these into 2 groups based on the MSA; SUE group (n=107, MSA < 5 mm2) vs. non-SUE group (n=286, MSA ≥ 5 mm2). Results: Significant intimal hyperplasia (IH) was defined as IH area more than 50% area of stent. Overall, 25 lesions (23.3%) among SUE group had IVUS-defined ISR, whereas 30 lesions (10.4 %) among non-SUE group has IVUS-defined ISR (p=0.005). Multivariate logistic regression for the determinant for the IVUS-defined ISR in the each groups were compared. In SUE group, diabetes mellitus [odd ratio (OR) =3.03, confidence interval (CI) =1. 10-8.39, p=0 .0014] and long stent (> 28mm) (OR = 3.9, CI = 1.2-12.6, p=0.017) were predictors for IVUS-defined ISR, however in non-SUE group, diabetes mellitus (OR = 2.99, CI = 1.29-6.92, p=0.014) and age (OR = 1.24, CI = 1.02-2.56, p=0.017) were predictors for IVUS-defined ISR at follow-up.
Conclusion:
The difference of predictors for occurrence of ISR at follow-up might exist between SUE and non-SUE group. However, in general, diabetes mellitus showed a universal predictor for occurrence of ISR at follow-up regardless of under-expansion after DES implantation.
TCT-203 No Difference In Long-term Major Adverse Cardiac Event Rates Between Paclitaxel-eluting and Sirolimus-eluting Stents
James Philip Howard, Zia Buckhoree, Dan A Jones, Sean M Gallagher, Krishnaraj S Rathod, Ajay K Jain, Charles Knight, Anthony Mathur, Andrew Wragg Department of Cardiology, Barts and the London NHS trust, London, United Kingdom Background: Previous studies have demonstrated similar outcomes over the short to mid-term in patients treated with paclitaxel-eluting stents (PESs) or sirolimus-eluting stents (SESs). However there is limited 'real-world' data investigating long term outcomes. This study compared outcomes at 5 years following revascularisation in the two patient groups. Methods: 4252 consecutive patients underwent PCI with either paclitaxel-eluting (PES) or sirolimus-eluting stents (SES) at a single centre (October 2003 -January 2011). Indications for PCI included stable and unstable angina. Left main and vein graft lesions were excluded. Demographic and procedural data were collected at the time of intervention. All-cause mortality data were obtained from the Office of National Statistics via the BCIS/CCAD national audit out to a median of 4.0 years (CI 2.4 -5.6 years). Primary end point was major adverse cardiac events (MACE), a composite of all-cause mortality, myocardial infarction and target vessel revascularization (TVR). Results: There were 1592 (37%) patients treated with SES and 2,660 (63%) patients treated with PES. Baseline demographic, angiographic, and procedural characteristics were similar between the two groups. At 5 years there were no statistical differences in MACE between the stent types (SES 15.9% 95% CI 12.7-19.4 vs. PES: 16.5% 95% CI 12.6-20.3, p=0.9). This consisted of similar rates of all-cause mortality (10.1% vs. 9.3%, p=0.4), TVR (5.3% vs. 6.4%, p=0.4), and stent thrombosis (2% vs. 1.8%, p=0.5). In diabetic patients (n=1172 (28%)), there was a trend towards lower MACE favouring PES but this did not reach statistical significance (19% vs. 24%, p=0.16) .
Conclusion:
This observational analysis of PES and SES-treated patients demonstrates similar overall safety and efficacy over a 5-year follow-up period with low rates of TVR.
